Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

12.57
-0.0900-0.71%
Volume:378.76K
Turnover:4.79M
Market Cap:1.12B
PE:-3.73
High:12.76
Open:12.71
Low:12.55
Close:12.66
52wk High:13.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:0.56
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:23.04
PE(LYR):-3.95

Loading ...

Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial

TIPRANKS
·
May 13

Kura updates ziftomenib-plus-7+3 trial data in frontline AML at EHA 2026

Reuters
·
May 12

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

GlobeNewswire
·
May 12

Kura Oncology Inc expected to post a loss of 63 cents a share - Earnings Preview

Reuters
·
May 09

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

GlobeNewswire
·
May 06

Kura Oncology to report first-quarter 2026 financial results after market close

Reuters
·
May 05

Kura Oncology grants 133,750 inducement stock options priced at $8.77 per share

Reuters
·
May 04

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 04

Kura Oncology, Kyowa Kirin dose first patient in Japan Phase 2 ziftomenib trial

Reuters
·
Apr 28

H.C. Wainwright Reaffirms Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Apr 20

Barclays Sticks to Their Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Apr 20

Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating

TIPRANKS
·
Apr 18

Sector Update: Health Care Stocks Higher Pre-Bell Friday

MT Newswires Live
·
Apr 17

BUZZ-Kura Oncology rises as kidney cancer combo shows early promise

Reuters
·
Apr 17

Kura says darlifarnib-cabozantinib trial posts 44% response rate in pretreated ccRCC

Reuters
·
Apr 17

Kura Oncology Inc - Reports Manageable Safety and Tolerability Profile in Rcc Patients

THOMSON REUTERS
·
Apr 17

Kura Oncology Inc - Treatment Durations Reached 56 Weeks; One-Third Remained on Therapy at Data Cut-off

THOMSON REUTERS
·
Apr 17

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

THOMSON REUTERS
·
Apr 17

Kura Oncology Initiated at Buy by Lake Street

Dow Jones
·
Apr 14

Kura Oncology announces annual shareholder meeting via webcast

Reuters
·
Apr 11